If you've been told you have fatty liver disease, struggle with obesity or type 2 diabetes, or have noticed persistent fatigue and abdominal discomfort, you may be at risk for MASH, a progressive liver condition that can lead to serious and irreversible damage. When left untreated, MASH can silently scar your liver over time, advancing to cirrhosis, liver failure, and liver cancer.
Our specialists are here to provide thorough evaluation, accurate diagnosis, and personalized treatment plans to help you slow disease progression and protect your long-term liver health. Don't wait for symptoms to appear; early intervention can preserve your liver and your quality of life. Call today at (704) 452-4383 to schedule an appointment!
MASH stands for metabolic dysfunction-associated steatohepatitis and is an advanced, more serious form of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). While MASLD involves fat accumulation in the liver, MASH goes further, causing active inflammation and liver cell damage that can lead to fibrosis, cirrhosis, and liver failure. MASH is one of the leading causes of liver transplants in the United States and is considered a significant and growing public health concern.
Contact Us Today About MASHMASH often progresses silently with no symptoms in the early stages. As the condition advances, some people may experience:
MASH develops when fat accumulation in the liver triggers inflammation and damage to liver cells. This process is closely tied to metabolic dysfunction and is strongly associated with conditions that affect how the body processes fat, sugar, and energy. Insulin resistance is considered a central driver of MASH, causing excess fat to build up and inflame the liver. Obesity, particularly excess abdominal fat, significantly increases the risk of developing MASH, as do an unhealthy diet high in refined carbohydrates and saturated fats, a sedentary lifestyle, and the presence of metabolic syndrome.
MASH diagnosis involves various tests and procedures, which our gastrointestinal specialists in Salisbury and Concord use, including:
Certain factors can increase the risk that someone will develop MASH. These risk factors include:
Left undiagnosed and untreated, MASH can cause long-term health complications, such as:
Lifestyle modification remains the cornerstone of MASH treatment. Losing 7-10% of body weight through a healthy diet and regular exercise can significantly reduce liver inflammation and fibrosis. In 2024, the first FDA-approved medication specifically targeting MASH became available, offering an additional treatment option for those with moderate to advanced fibrosis. Managing related metabolic conditions like diabetes, high cholesterol, and high blood pressure is also essential. Your specialist will work with you to build a comprehensive, personalized treatment plan based on your disease stage and overall health.
MASLD, or metabolic dysfunction-associated steatotic liver disease, is the umbrella term for liver disease caused by fat accumulation related to metabolic dysfunction. MASH is a more advanced and serious stage of MASLD. While MASLD involves fat in the liver without significant inflammation, MASH involves active liver cell inflammation and damage that can progress to fibrosis and cirrhosis. Not everyone with MASLD will develop MASH, but those who do face a higher risk of serious complications.
No, not everyone with MASH will develop cirrhosis. The rate of progression varies widely from person to person. Some individuals have stable disease for many years, while others progress more quickly. Factors like obesity, diabetes, genetics, and ongoing inflammation influence how fast the disease advances. Early diagnosis and proactive lifestyle changes significantly reduce the risk of progression to cirrhosis and other serious complications.
Yes, MASH and NASH refer to the same condition. The terminology was updated in 2023 by leading liver disease organizations to better reflect the metabolic nature of the disease. The new name removes the stigma associated with the "non-alcoholic" label. If you were previously diagnosed with NASH, your condition is now referred to as MASH and your treatment approach remains the same.
No, MASH is not caused by alcohol use. It develops as a result of metabolic dysfunction, primarily driven by obesity, insulin resistance, and poor diet. This is one of the reasons the condition was renamed from NASH to MASH, to more accurately reflect its metabolic origins. That said, people with MASH should avoid or strictly limit alcohol consumption, as it can worsen liver inflammation and accelerate damage.
In its early to moderate stages, MASH can potentially be reversed or significantly improved with lifestyle changes. Studies show that losing 7-10% of body weight can reduce liver inflammation and even reverse fibrosis in some patients. The first FDA-approved medication for MASH also demonstrated the ability to reduce scarring in clinical trials. However, once cirrhosis develops, the damage is largely irreversible, making early intervention critical.
People diagnosed with MASH typically require regular monitoring to track disease progression and treatment response. This may include periodic blood tests to assess liver enzyme levels, imaging studies like FibroScan or MRI to evaluate fibrosis, and routine check-ins with your gastroenterologist or hepatologist. Those with advanced fibrosis or cirrhosis may also need regular screenings for liver cancer. Your specialist will determine the appropriate monitoring schedule based on your individual situation.
A MASH diagnosis should be taken seriously. Unlike simple fatty liver, MASH involves active inflammation that can lead to progressive liver damage, cirrhosis, liver cancer, and liver failure. It is one of the leading causes of liver transplants in the United States. However, with early diagnosis, lifestyle modifications, and appropriate medical treatment, many people can slow or stop disease progression and protect their long-term liver health.
Yes, children can develop MASH, and rates have been rising alongside childhood obesity. Pediatric MASH is increasingly recognized as a significant health concern. Children with obesity, type 2 diabetes, or metabolic syndrome are at higher risk. Symptoms in children can be similar to those in adults, and lifestyle interventions including healthy diet and increased physical activity are the primary treatment approach.
A Mediterranean-style diet is widely recommended for people with MASH. This approach emphasizes vegetables, fruits, whole grains, legumes, fish, and healthy fats like olive oil, while limiting red meat, processed foods, added sugars, and refined carbohydrates. Avoiding alcohol and sugary beverages is particularly important. Reducing overall calorie intake to support modest weight loss is also a key dietary goal, as even small reductions in body weight can have a significant positive impact on liver health.
In 2024, the FDA approved the first medication specifically indicated for MASH with moderate to advanced fibrosis, representing a major milestone in treatment. Your gastroenterologist can evaluate whether you are a candidate for this therapy based on your disease stage and overall health. Medication is used alongside lifestyle changes, which remain the foundation of MASH management.
